Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daewoong Pharmaceutical To In-license Almirall's COPD drug Eklira In Korea

This article was originally published in PharmAsia News

Executive Summary

Daewoong signs in-licensing deal just one week before Eklira – a product with a history of clinical setbacks – faces U.S. FDA advisory committee meeting.

You may also be interested in...



Korean Analysts Retain Optimism For Daewoong Pharmaceutical On Early Pipeline and In-licensing

SEOUL - Daewoong Pharmaceutical has beefed up its product lineup and increased R&D investment for high-growth therapeutic areas, which has brightened the company's outlook in the eyes of some Korean analysts despite stronger generics competition in 2011

Positive COPD Data Allows Forest To File For Approval of Eklira in 2011

Forest Laboratories and Spain's Almirall report positive late-stage data for their COPD drug, paving the way for 2011 regulatory filings in the U.S. and EU.

Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III

Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1129947

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel